| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种新的多肽－呼吸链NADH脱氢酶10和编码这种多肽的多核苷酸 | CN99125654.9 | 1999-12-21 | CN1300836A | 2001-06-27 | 毛裕民; 谢毅 |
| 本发明公开了一种新的多肽－呼吸链NADH脱氢酶10,编码此多肽的多核苷酸和经DNA重组技术产生这种多肽的方法。本发明还公开了此多肽用于治疗多种疾病的方法,如恶性肿瘤,血液病,HIV感染和免疫性疾病和各类炎症等。本发明还公开了抗此多肽的拮抗剂及其治疗作用。本发明还公开了编码这种新的呼吸链NADH脱氢酶10的多核苷酸的用途。 | ||||||
| 2 | ND2肽和神经疾病的治疗方法 | CN201180047059.0 | 2011-09-28 | CN103282379B | 2016-01-06 | 迈克尔·蒂米安斯基; 李荣文; 乔纳森·戴维·加曼 |
| 本发明部分基于识别ND2的核心区，该核心区负责与Src相互作用，涉及ND2的289-321残基中的区域并且尤其是ND2的310-321残基中的区域。包括该区域、与该区域重叠或这个区域之中的肽可以用于抑制ND2与Src的相互作用。这种相互作用的抑制可用于治疗或预防神经疾病和失调、疼痛和癌症。 | ||||||
| 3 | ND2肽和神经疾病的治疗方法 | CN201180047059.0 | 2011-09-28 | CN103282379A | 2013-09-04 | 迈克尔·蒂米安斯基; 李荣文; 乔纳森·戴维·加曼 |
| 本发明部分基于识别ND2的核心区，该核心区负责与Src相互作用，涉及ND2的289-321残基中的区域并且尤其是ND2的310-321残基中的区域。包括该区域、与该区域重叠或这个区域之中的肽可以用于抑制ND2与Src的相互作用。这种相互作用的抑制可用于治疗或预防神经疾病和失调、疼痛和癌症。 | ||||||
| 4 | ACID-TOLERANT YEAST CELL, METHOD OF PRODUCING ORGANIC ACID USING THE SAME, AND METHOD OF PRODUCING THE YEAST CELL | US15222646 | 2016-07-28 | US20170029853A1 | 2017-02-02 | Hunsu Chu; Hwayoung Cho; Jinhwan Park; Dongsik Yang; Hongsoon Rhee; Kwangmyung Cho |
| Provided is an acid-tolerant yeast cell, a method of producing an organic acid by using the yeast cell, and a method of producing the yeast cell resistant to acid. | ||||||
| 5 | RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE | US14440746 | 2013-11-07 | US20150299672A1 | 2015-10-22 | Bart DE STROOPER; Patrik VERSTREKEN; Vanessa MORAIS EPIFÂNIO |
| The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm. | ||||||
| 6 | ND2 peptides and methods of treating neurological disease | US13842848 | 2013-03-15 | US09073976B2 | 2015-07-07 | Michael Tymianski; Rongwen Li; Jonathan David Garman |
| The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer. | ||||||
| 7 | Restoring phosphorylation of a novel PINK1 substrate to treat parkinson's disease | US14440746 | 2013-11-07 | US09879233B2 | 2018-01-30 | Bart De Strooper; Patrik Verstreken; Vanessa Morais Epifânio |
| The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm. | ||||||
| 8 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C VIRUS INFECTIOUS DISEASE | US15032717 | 2014-10-28 | US20160271229A1 | 2016-09-22 | Seung Kew YOON; Jung Hee KIM; Won Hee HUR; Mi La CHO; Jung Eun CHOI; Eun Byul LEE |
| The present invention relates to a pharmaceutical composition for preventing or treating hepatitis C virus (HCV) infectious disease. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating HCV infectious disease or an antiviral composition for HCV, containing at least one selected from the group consisting of: GRIM19 protein or a fragment thereof; and a gene encoding the protein or a fragment of the protein. | ||||||
| 9 | Method for identifying smoker or ex-smoker at risk of chronic obstructive pulmonary disease | US12648964 | 2009-12-29 | US08530180B2 | 2013-09-10 | Dominic M. Desiderio; Xianquan Zhan |
| Specific nitroprotein biomarkers may be used as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD. | ||||||
| 10 | ND2ペプチドおよび神経疾患の治療方法 | JP2013530433 | 2011-09-28 | JP6073230B2 | 2017-02-01 | ティミアンスキ, マイケル; リ, ロンウェン; ガーマン, ジョナサン デイビッド |
| 11 | Nd2 treatment methods of peptide and nerve disease | JP2013530433 | 2011-09-28 | JP2014505655A | 2014-03-06 | マイケル ティミアンスキ，; ロンウェン リ，; ジョナサン デイビッド ガーマン， |
| 本発明は、Ｓｒｃとの相互作用に関与するＮＤ２のコア領域を、ＮＤ２の残基２８９〜３２１内、より具体的にはＮＤ２の残基３１０〜３２１内に、特定することに部分的に基づいている。 この領域を含む、この領域に重なる、またはこの領域内からのペプチドは、ＮＤ２のＳｒｃとの相互作用を阻害するために使用することができる。 この相互作用を阻害することは、神経疾患および神経障害、疼痛ならびに癌の治療および予防に有用である。
【選択図】図１８ |
||||||
| 12 | Acid-tolerant yeast cell, method of producing organic acid using the same, and method of producing the yeast cell | US15222646 | 2016-07-28 | US10053714B2 | 2018-08-21 | Hunsu Chu; Hwayoung Cho; Jinhwan Park; Dongsik Yang; Hongsoon Rhee; Kwangmyung Cho |
| Provided is an acid-tolerant yeast cell, a method of producing an organic acid by using the yeast cell, and a method of producing the yeast cell resistant to acid. | ||||||
| 13 | ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE | US13842848 | 2013-03-15 | US20140274906A1 | 2014-09-18 | Michael Tymianski; Rongwen Li; Jonathan David Garman |
| The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer. | ||||||
| 14 | NITROPROTEIN BIOMARKERS FOR COPD | US12648964 | 2009-12-29 | US20100183578A1 | 2010-07-22 | Dominic M. DESIDERIO; Xianquan Zhan |
| Specific nitroprotein biomarkers may be used as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD. | ||||||
| 15 | NADH dehydrogenase subunits | US907706 | 1997-08-08 | US5919686A | 1999-07-06 | Olga Bandman; Jennifer L. Hillman; Karl J. Guegler; Purvi Shah |
| The invention provides two human NADH dehydrogenase subunits (HNDS) and polynucleotides which identify and encode HNDS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HNDS. | ||||||
| 16 | ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE | EP11833072 | 2011-09-28 | EP2621945A4 | 2014-05-07 | TYMIANSKI MICHAEL; LI RONGWEN; GARMAN JONATHAN DAVID |
| The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer. | ||||||
| 17 | ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE | EP11833072.9 | 2011-09-28 | EP2621945A2 | 2013-08-07 | TYMIANSKI, Michael; LI, Rongwen; GARMAN, Jonathan David |
| The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src. Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer. | ||||||
| 18 | NITROPROTEIN BIOMARKERS FOR COPD | EP09799273.9 | 2009-12-18 | EP2373998A1 | 2011-10-12 | DESIDERIO, Dominic M.; ZHAN, Xianquan |
| The invention relates to the use of specific nitroprotein biomarkers as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD. | ||||||
| 19 | RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE | EP13792867.7 | 2013-11-07 | EP2917342B1 | 2017-06-21 | DE STROOPER, Bart; VERSTREKEN, Patrik; MORAIS EPIFÂNIO, Vanessa |
| The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm. | ||||||
| 20 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF | EP15799189.4 | 2015-05-27 | EP3148565A2 | 2017-04-05 | WILSON, D. Travis |
| Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2. | ||||||
QQ群二维码
意见反馈
意见反馈